Table 2.
Clinicopathologic patient characteristics and univariate survival analysis
| Variable | Patients (n = 112) | 5-y OS Rate (%) | P value | 5-y MFS Rate (%) | P value |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 67 (59.8%) | 57.8% | 1.538 | 47.2% | 0.316 |
| Female | 45 (40.2%) | 53.2% | 43.6% | ||
| Age at diagnosis | |||||
| ≤20 | 74 (66.1%) | 54.3% | 0.621 | 37.8% | 0.217 |
| >20 | 38 (33.9%) | 60.1% | 42.3% | ||
| Tumor Location | |||||
| Femur | 39 (34.8%) | 62.3% | 0.458 | 54.2% | 0.625 |
| Tibia | 28 (25.0%) | 53.2% | 47.8% | ||
| Humerus | 17 (15.2%) | 59.4% | 50.7% | ||
| Fibula | 15 (13.4%) | 76.4% | 68.3% | ||
| Others | 13 (11.6%) | 68.9% | 58.5% | ||
| Histological classification | |||||
| Osteoblastic | 67 (59.8%) | 47.8% | 0.358 | 46.3% | 0.631 |
| Chondroblastic | 36 (32.1%) | 58.4% | 53.6% | ||
| Others | 9 (8.1%) | 71.2% | 67.2% | ||
| Metastasis | |||||
| Yes | 64 (57.1%) | 25.3% | <0.001 | 11.7% | <0.001 |
| No | 48 (42.9%) | 62.8% | 76.2% | ||
| Histological grade | |||||
| I | 27 (24.1%) | 63.2% | 0.012 | 65.2 | 0.026 |
| II | 53 (47.3%) | 52.7% | 37.8 | ||
| III | 32 (28.6%) | 26.4% | 27.4 | ||
| Enneking staging | |||||
| I | 28 (25.0%) | 86.2% | <0.001 | 76.5% | <0.001 |
| II A | 46 (41.1%) | 63.2% | 60.1% | ||
| II B | 31 (27.7%) | 26.3% | 23.7% | ||
| III | 7 (6.2%) | 2.8% | 0% | ||
| SEMA3F | |||||
| Negative | 36 (32.1%) | 41.3% | 0.013 | 37.8% | <0.001 |
| Positive | 76 (67.9%) | 76.2% | 64.5% | ||
Abbreviation: OS, Overall survival; MFS, Metastasis-free survival; SEMA3F, Semaphorin-3F.